Speaker Profile
M.B.A, CEO, MedySapiens Inc.
Biography
Sanggoo Kang is CEO & founder of MedySapiens, Inc. pursuing perfect harmony of Biomedical and Data Science (Bioinformatics and Artificial Intelligence combined). Previously, Kang was COO/VP at DNA Link, one of the largest genomics service providers in Korea. After getting MBA from Duke in 1999, Kang worked for various companies in the US mostly in Hi-Tech marketing and business development area. They include 3M, Toshiba America, Samsung Electronics America, Nortel Networks and JP Morgan. Before coming to the US, Kang used to work for LG U+ as Telecom engineer. Kang has Electrical Engineering BS degree from Seoul National University (Seoul, Korea) and MBA from Duke University. Kang has diversified background; Engineering and Business, Information & Communication Technology and Bio Tech, and global exposure.
Clinical Dx Showcase:
MedySapiens, Inc.
MedySapiens provides rare disease genetic variant diagnostic solution for patients especially in NICU (Neonatal Intensive Care Unit), where the most genetic disease suspects gather spontaneously. Its products are composed of two; NEOseq_ACTION panel and MedyCVi genetic variant analysis solution.
Newborns' Rapid Rare Disease Diagnostic Solution
NEOseq_ACTION detects, isolates, and amplifies 254 genes, potentially causing 220 rare diseases actionable and relatively common. MedyCVi, genetic variant analysis solution includes MedyPatho (Machine Learning scoring pathogenicity) and MedySearch (genetic variant re-evaluation searching through PubMed to dig confirmed diagnostic cases, therapeutics and prognosis).
